Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 4/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
| ▸ | CTRC | Q99895 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.38 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3324241 | 0.77 | AURKA (0.44) | MEN1KMT2A | |
| SCHEMBL7375985 | 0.77 | MKNK1 (0.53) | CHEK2MAP4K4MKNK1MKNK2NPC1 | |
| SCHEMBL4394098 | 0.76 | MAPT (0.65) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL6631157 | 0.76 | CHEK2 (0.54) | CHEK2MAP4K4MAPTCTRCPARP1 | |
| SCHEMBL1532386 | 0.76 | SIRT2 (0.45) | MAPTSIRT2MEN1KMT2ANPC1 | |
| SCHEMBL1148141 | 0.74 | LOXL2 (0.42) | — | |
| SCHEMBL8384783 | 0.74 | MAPT (0.44) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL12102886 | 0.74 | CXCL12 (0.46) | MAPTMEN1KMT2A | |
| SCHEMBL2989224 | 0.73 | MAPT (0.43) | MAPTMEN1KMT2ARAB9A | |
| SCHEMBL28787855 | 0.72 | HPGD (0.40) | CHEK2MAPTCTRCMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130066069-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-14 | — | — | US | disclosed |
| US-20090298844-A1 | ABL KINASE INHIBITION | VERTEX PHARMACEUTICALS INCORPORATED | 2009-12-03 | — | — | US | disclosed |
| WO-2007136615-A2 | COMBINATION CANCER THERAPY | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298844-A1 | ABL KINASE INHIBITION | ABL2, ABL1, PRKDC | CHEK2 540/4885MAP4K4 75/4885MKNK1 193/4885 |
| US-20130066069-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | AURKA, AURKC, AURKB | CHEK2 18/4885MAP4K4 182/4885MKNK1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.